OmniAb, Inc. (OABI) Earnings Call Transcript & Summary
August 10, 2023
Earnings Call Speaker Segments
Kurt Gustafson
executiveThanks, operator, and good afternoon to all of you. I appreciate everyone taking the time to participate in our conference call covering the financial results for the second quarter of 2023. Slides have been prepared to go along with today's comments, and you can find them in the Investors Section on our site, omniab.com. Before we get started, I want to remind those listening that remarks delivered on this call will contain forward-looking statements as defined under the federal securities laws; such forward-looking statements carry risks and uncertainties that might lead actual results to differ materially from any results that are anticipated. The cautionary statements included in today's press release and in our SEC filings qualify these forward-looking statements. It's important to note that this conference call includes time-sensitive information that is accurate only as of today's live broadcast date, August 10th, 2023. Unless the law requires otherwise, OmniAb assumes no obligation to revise or update any forward-looking statements to reflect events or circumstances occurring after the date of this call. With me on today's call is Matt Foehr, who serves as President and CEO of OmniAb. On this call, Matt and I will walk through highlights regarding the company's operations, updates on our partners and technology, and our recent financial results. Once the prepared remarks are finished, we'll open up the call for questions. With that said, I'll hand the call over to Matt.
Matt Foehr
executiveThanks, Kurt. Hi everyone, and we appreciate you joining this call about our Q2 results. First, I'll take you through a business overview, which appears on Slide 4 in the deck. OmniAb's approach relies on our proprietary discovery tech platform, designed to assist partners in finding breakthrough therapeutics quickly and with efficiency. In short, under this model we license innovative technologies to our partners. What distinguishes OmniAb in the market is offering the widest variety of host systems for fully human bispecific, fully human, and bispecific antibody discovery, including the only four species platform in the industry — spanning transgenic mice, rats, chickens, and cow-based technologies. An increasing share of the antibodies now in clinical trials originate from our technology, thanks to our partners. And the adaptability of our platform continues to be shown by the modalities and formats our partners are using, whether pre-clinically or clinically. We offer flexibility to meet our partners' changing scientific needs, because we think that creating extensive and varied collections of high-quality antibodies increases the odds of successfully optimizing the therapeutic characteristics you want. The biological intelligence of our transgenic animals is what powers our technology and core capabilities, and our innovative high-throughput screening along with other technologies makes it even more powerful. Seventy-four partners currently have access to either our technology or OmniAb antibodies, and those partners are running more than 300 programs spanning different phases of research and development. Within the drug industry, antibodies rank among the segments growing most quickly, and in just a couple of years the market is projected to exceed $250 billion; given the distinctive and growing set of technologies we offer, we think we are ideally situated to take advantage of that opportunity. Back in May, we rolled out something we're now calling OmniDeep. It's a collection of computational, or in silico, tools—things like structural modeling, big antibody databases spanning multiple species, molecular dynamics simulations, AI, plus machine and deep learning sequence models. These can be applied across all our technology platforms to make our partners' discovery work even better. On top of that, we're planning to bring out our new heavy chain-only OmniChicken, which will carry the OmniDab brand, sometime in Q4 of this year. As for more specifics on Dab and why we're so enthusiastic about it, I'll hold off until we actually launch it later this year. Moving to the next slide, I'd like to restate something: our company and our team are driven by a mission — helping innovative pharmaceutical products get discovered quickly by advancing the boundaries of drug discovery technologies. As Slide 6 illustrates, we're set up for ongoing growth thanks to the fresh license agreements we entered into in the second quarter. During Q2, four new platform license agreements were finalized by our team: one apiece with Merck Inc. and Neurocrine Biosciences, plus platform deals involving Stanford University and Seattle Children's Hospital. With respect to Merck, this marks a new agreement, and it's with the U.S. There's Merck & Company — distinct from Germany's Merck KGaA, a company we've also signed an agreement with. When the quarter ended, our roster of active partners stood at 74, whereas roughly a little more than 60 partners were on board at this point a year earlier. Across the industry, among a diverse group of top global pharma players, enthusiasm for what our discovery platform offers continues to grow, which positions us to capitalize on the strong scalability of our business model. We're excited to add partners like Merck Inc. They're a global industry leader focused on using cutting-edge science to make people's lives better. That brings more strength to the partner roster we're building. From where we sit, it shows that our discovery technologies work well and are efficient, that we've got internal know-how when it comes to scientific collaboration services, that we take the time to really understand what our partners need now and down the road, and that we remain committed to innovating. Turning to Slide number 8, the number of active programs climbed to 305. Of those, 29 were in the clinic, either going through regulatory review or already cleared for commercialization, as of the close of Q2. During Q2, our portfolio grew by a net of four programs. One thing worth noting: our program count is always reported after subtracting attrition, because some level of attrition is simply normal for pharma. This time around, the only attrition we saw was within the discovery portion of the pipeline we run with partners. Over on the right side of this slide, that pie chart shows how our 305 programs split across development stages. Within discovery, there are 261 programs, and another 15 have now reached preclinical. As of the close of June, the programs our partners are running in the clinic broke down this way: 22 in Phase I, a pair in Phase II, a single one in Phase III, plus another that's right now going through regulatory review. Three drugs have received approval that are built on antibodies from OmniAb, and we're booking royalty revenue from commercial sales in China of Zimberelimab and sugemalimab, and both of those are additionally being developed in other regions; during the quarter we also witnessed encouraging advancement across the programs, since three programs went from discovery into preclinical, two moved out of preclinical and into their initial human clinical trials, and one Phase III program advanced to a regional filing for approval, which appears as BLA stage on the pie chart on the right side of Slide number 8. As I said before, our portfolio is large and expanding, with a diversified group of partners employing many different formats and modalities. One more thing worth pointing out: we finished the second quarter with 305 active programs, compared with 270 a year earlier — and keep in mind that figure already accounts for programs we lost. Even with the difficulties this industry is facing, such as a shifting financing landscape and tighter funding, particularly for the smaller companies we compete with, we keep growing our portfolio thanks to both new and long-standing partners. It's completely surprising to all of us that macro conditions are able to affect how quickly certain of our business metrics grow, and even though the count of net new program additions is somewhat below what we saw a year ago, OmniAb stands on very strong footing for ongoing growth, given that both active programs and active partners are on the rise. Let's turn to Slide 9 now. Back in the second quarter, I noted that two fresh programs had reached the clinic: Immunovant kicked off a Phase I clinical trial for IMVT-1402, a subcutaneous FcRn inhibitor. Also, Genor Biopharma kicked off a Phase I/II trial examining how safe and tolerable GLS-012 is, plus its early efficacy signals, when given alone and together with GLS-010, in patients whose advanced solid tumors got worse following standard therapy; during the first half of this year, three fresh programs have made it into the clinic, and we think possibly one or two more could enter the clinic before the year wraps up. I want to note that back when 2023 began, we said we expected three to five new programs to reach the clinic over the course of this year.
Matt Foehr
executiveAs we wrapped up June, we'd already secured three, and right now our focus is on possibly reaching as many as four to five additional clinical programs this year. Our partners made plenty of public announcements about clinical and commercial advancements throughout Q2 and in recent weeks. On Slide 10 here, I'll highlight several of those, starting with batoclimab. During Q2, we received milestone revenue because batoclimab advanced into pivotal trials for two additional indications, CIDP and TED. Those indications add to the Phase III effort that kicked off in generalized myasthenia gravis earlier this year. Harbour BioMed also reported that China's NMPA has agreed to review its Biologics License Application for generalized myasthenia gravis treatment. For the same condition, HanAll stated that a Phase III study in Japan is slated to kick off later this year. Shifting to IMVT-1402, the next-generation anti-FcRn, I pointed out that Immunovant has launched a Phase I study looking at safety, tolerability, and pharmacodynamics. According to the company, first data ought to be available during this year's second half. Cessation Therapeutics, a partner we brought on more recently, announced it has been cleared to start a Phase I clinical trial. CSX-1004 came out of work done alongside Scripps Research Institute and was subsequently licensed to Cessation so it could be developed. Cessation is working on a drug intended to stop fentanyl overdoses — a use case where patients clearly have a serious and pressing need that isn't being met. Aptevo Therapeutics shared results on APVO436, its dual-target AML therapy candidate, and plans to begin a pair of Phase II studies in AML patient groups. Last, inside one of our ion channel partnerships with GSK, we once again hit a research milestone for small molecule inhibitors aimed at a genetically validated target tied to neurological conditions. OmniAb earned a $2 million progression payment as a result, and Kurt will walk through how that gets accounted for. This GSK program stands out to us because it demonstrates the capabilities of our ion channel and transporters technology platform, which is highly differentiated. Ion channels play essential roles in many biological functions where cells change quickly, and they offer treatment possibilities across a wide spectrum of conditions — among them neurological disorders, metabolic diseases, pain, cancer, and infectious diseases, plus numerous others. Because of this, finding drugs that act on ion channels represents an attractive opening, even though the industry has found it difficult to develop medicines against these valuable targets. At OmniAb, our ion channel platform draws on our proprietary know-how spanning biological assays, medicinal chemistry, and in silico as well as computational chemistry tools, which allows us to discover therapeutics aimed at ion channels across multiple formats and modalities. Our view is that the unique strengths at the heart of what we do can help our partners move their drug discovery work forward for this class of targets. We keep growing what we're able to offer here, and we think the ion channel specialists on our team are among the most seasoned you'll find anywhere. We hold a large set of custom-built cell lines, reagents, and assays, all designed to accelerate how quickly ion channel therapies get discovered and developed. That's what pulls partners toward this part of our technology and our know-how. Because these targets tend to be tougher to pin down and come with more value, we structure our collaboration deals with that in mind. Such deals grant exclusivity across different targets, which means they come with larger milestone payments and bigger royalty rates than what we normally receive under standard platform access agreements. With GSK, we have an arrangement covering 2 neurology targets currently in the discovery phase, and with Roche, we have another partnership involving 3 undisclosed targets that are likewise in discovery. Altogether, across just these 5 programs, we stand to collect 1 billion in milestones, plus royalties if any program reaches commercialization; this final slide from me, Slide 13 in our deck, underscores the main areas we are concentrating on moving forward. This section explains our belief that we're set up strongly to expand in the coming period, and that we can make a durable mark on our sector and, ultimately, on human health across the globe. Our operation scales easily, and we're focused on adding more partners and expanding programs by continually funding tools and breakthroughs that drive the identification and creation of promising treatment candidates. Prioritizing stakeholders and generating value for them is fundamental to how we operate, and that focus is developed jointly with our board of directors, and it's embedded in every person who works here as well. Speaking of our board, I should also mention on today's call that earlier this week, we sadly announced that Sunil Patel, a beloved member of OmniAb's Board, has passed away. Sunil was a accomplished biotech leader, a colleague of many years, and someone who helped design the very thing we're creating here at OmniAb. I'd also say that all of us here are paying tribute to what Sunil gave and left behind as we continue our vital work, push our technology further, and expand our business. So, just before handing things over to Kurt again, I want to wrap up by noting that we're eager to continue updating investors as we execute on our plan. With that said, I'll now turn things back to Kurt so he can walk us through the financial results for the second quarter. Kurt?
Kurt Gustafson
executiveThanks, Matt. Just a quick note before we start — the prior year figures we're reporting were put together on a carve-out basis. They came from Ligand's historical accounting records and assume OmniAb operated as a standalone business. Because of that, some year-over-year comparisons don't really capture what's actually happening in the underlying business. That's especially the case for operating expenses, since corporate structure and reporting methods differ. As you know, OmniAb's revenue comes from a few places: upfront payments from partners who want access to our technology stack, service contract payments when we perform discovery work for partners, milestone payments that usually tie to clinical progress, and royalties on net sales from our partners' programs. Now to our Q2 numbers specifically. Total revenue for the second quarter of 2023 came in at $6.9 million, versus $7.2 million in the same quarter last year. License and milestone revenue rose thanks to milestones reached this quarter, largely driven by progress on batoclimab — in particular, the launch of additional pivotal studies for two new indications. That milestone revenue gain was offset by a drop in service revenue, which stems from a few factors. First, our share of work on certain programs is finished, and those programs have been transitioned to our partners' R&D teams. So we won't book service revenue from them anymore, though we could still earn milestones and royalties if they move forward. Second, the research period for one of our GSK ion channel programs was lengthened by roughly one and a half years. From an accounting standpoint, that extension meant the initial $7 million upfront payment, which had been amortized across the original research period, had its amortization schedule recalculated for the new research period length. That produced a one-time negative adjustment of $1.7 million in the quarter. Eventually the entire $7 million gets recognized — it's just that revenue recognition will now be stretched across the new, longer research period. Third, regarding the GSK program that hit the $2 million research progression milestone, that milestone counts as service revenue and gets amortized over the program's research period. Since this program is a bit past the halfway mark of its research period, we recognized a bit more than half of the milestone this quarter, with the remainder to be amortized over what's left of the research period. Altogether, the amortization period change plus the new milestone recognition had a negative impact of roughly $500,000 in the quarter compared with what the trend would otherwise have been. Now on to operating expense. R&D expense for Q2 was $14.1 million, versus $11.5 million in the prior-year quarter. Like Q1, the rise was mainly driven by higher personnel costs and higher costs tied to our new facilities. General and administrative costs came in at $8.7 million, up from $5 million during the same quarter a year earlier, and that rise stems from adding more staff along with other expenses tied to operating as a company that recently went public. For the second quarter, our net loss reached $14.7 million, equating to $0.15 per share, compared with a net loss of $10.3 million, or $0.12 per share, during the equivalent period last year. Moving over to the balance sheet, we closed out the second quarter holding $103.1 million altogether in cash, cash equivalents, and short-term investments. Being a business that does not require heavy capital investment, our model scales extremely well. Although we remain dedicated to expanding the business and keeping our technology at the forefront, we also remain dedicated to putting our capital to work efficiently. Our expectation stays the same that by the close of 2023, our cash balance will be marginally above where it stood at the close of 2022, and that this cash position gives us enough runway to finance operations well into the future. Shifting to our quarterly results, I want to offer a few remarks regarding certain underlying trends we are observing. If we set aside the milestone revenue recognized specifically for teclistamab, our general expectation is that total revenue will increase. That said, most of our revenue over the near to medium term is going to arrive through milestone payments, and pinning down exactly when those milestones land can prove challenging. Consequently, on a quarterly basis, our revenue growth is likely to be somewhat uneven. When considering our operating expense moving forward, I mentioned last quarter that our actual Q1 2023 results would serve as a solid baseline from which we would grow. The second quarter's results matched that expectation, and we expect this pattern to persist going forward now that our operating expenses have become more predictable. Our forecast is that both R&D and G&A will increase modestly in the quarters ahead, with G&A spending rising at a slower pace than our R&D spending; with that said, I'd like to begin taking questions. Operator?
Puneet Souda
analystHi everybody, and thanks for taking our questions. Matt, I'll start with you. You laid out some of the difficulties the market is facing, and you acknowledged that this situation could materialize. Could you give us the flip side, though? Tell us how your partners are responding and what they're saying about the opportunities they can send your way, given the value and the cost savings you provide them. It would help to hear how they see things as they consider the discovery stages and then advance toward Phase I.
Matt Foehr
executiveSure, Puneet, and thanks. Matt here. Thanks for asking that. So one thing worth highlighting: during this quarter we definitely closed platform license deals with four additional partners. Those would be Merck and Neurocrine. Merck, as everyone knows, is a major name — a worldwide powerhouse in this business that has demonstrated real dedication to breakthrough science and to applying the most advanced technologies in order to create new therapies. As for Neurocrine, they bring more than three decades of achievement and pioneering work aimed at delivering treatments that have genuinely transformed lives for patients dealing with neurological conditions and disorders of the nervous system. On top of that, we formed new alliances with Stanford and Seattle Children's — two premier academic institutions, each dedicated to turning their discoveries in biology into fresh therapeutic options. Often, it isn't just the partners we already work with who reveal how much value we deliver — newcomers do that too. As for how we pull that off, we hold extensive, in-depth conversations with partners about the fields they care about and the reasons they believe our technologies open doors for them. Naturally, that turns into prospects for better success rates and a quicker timeline when it comes to identifying high-quality antibodies that can move into the clinic, which is precisely what draws them to sign licensing agreements with us. What I believe we're seeing now is wider acknowledgment of how steadfast we've been about pushing innovation forward, and I'd say that matters quite a bit too. Naturally, the way we innovate draws on the strong ties we've built with our partners. We have something we refer to as an intelligent feedback loop — through it, you pick up on the direction the industry is moving, and that shapes which innovations and investments we choose to pursue in our technology. Ultimately, what it comes down to is speed and opportunity, along with efficiency and the quality of the product — in this instance, the antibodies produced from our plasma.
Puneet Souda
analystUnderstood. With that question, what I was really hoping to find out is this: should the funding environment for biotech deteriorate further, might that create a chance for you to pick up additional share in the market? Let me also ask something about China. I realize you brought up GLS-012, the anti-LAG-3, which is in Phase I testing right now. Could you give us an update on what you're observing in China? Everyone is aware of the softness at the discovery stage there; by now that's common knowledge, so I'm curious what you're seeing, whatever detail you can share, from a geographic standpoint. Thank you.
Matt Foehr
executiveYes. Yes, Puneet, I'll handle that. Let me start with the China portion, and after that Kurt might be able to chime in and provide some additional perspective too. As you know, we shared this quarter that Gloria has begun clinical work in China, which is great to see. Seeing advancement in the clinic from our pipeline is always a good thing; we clearly have a few medicines approved in China that Kurt can likely speak to as well. Much of that, when it comes to the later-stage, visible programs coming from China, actually traces back to some quite early partnerships involving OmniRat that were established years ago. Those programs moved rapidly through the clinic, and then. Nearing the clinic, which truly reflects what you observe in our pipeline with certain assets of ours. Kurt, perhaps you'd like to say a bit more too?
Kurt Gustafson
executiveSure, Puneet. What I mean is that when it comes to whatever sales projections our partners might have, we simply aren't privy to any particular details. One of those partners did make public, back earlier in this year, that supply chain problems had occurred during the first half of the year, caused in part by difficulties related to COVID. That same partner also said they anticipate those supply chain problems being resolved, resolved during the second half of the year, and so their forecast was for sales to recover. Naturally, a royalty on that comes to us. On the earlier portion of what you asked, our partnerships are genuinely structured to bring into line the economics our partners hand over with, with achievement, correct? My belief is that in a tough, if the funding climate we're in is tough, our approach lends itself to keeping people using it, since they aren't handing over, or paying big amounts of money until they actually achieve something, let's say, finding a drug and truly getting it into the clinic. My belief is that opportunities exist in that area, and we are still seeing growth continue across our key metrics.
Puneet Souda
analystUnderstood — that's really useful. I'll rejoin the queue.
Kurt Gustafson
executiveAppreciate it, Puneet.
Robyn Karnauskas
analystHello, everyone. I really appreciate you fielding my questions. To kick things off, I have a pair that you may or may not be in a position to address. Could you share some insight into the way the platform's arrangement with Stanford operates and how it differs from the arrangements you have with pharma companies? For instance, what does the structure look like, if you're able to share anything? When it comes to your ion channel programs, do those come with more favorable economics, considering how rare it is to successfully create small molecules or biologics against those targets? My assumption would be that the economics are better since the value you bring is substantially greater.
Matt Foehr
executiveYes, Robyn, thank you. I'll take your second question first, regarding the ion channel programs. The brief response is indeed yes. Under the way those programs are set up, we provide exclusivity to the target — to that particular target — alongside those partners. What they gain access to includes not just technology and capability, but also novel cell lines, novel reagents, novel screening technologies, and so on. That in turn produces a distinct and more favorable economic structure. You know, the 5 programs that are featured in the deck today, for the ion channel and transporter collaboration — both of those are with GSK and with Roche; just those 5 programs carry a billion in milestones, plus royalties that exceed what our standard platform license agreements provide; those are assets we're enthusiastic about. Naturally, we featured the GSK program today, but the brief response is indeed yes. Turning to your first question about the various kinds of deals. Over recent quarters, we've leaned into not just license agreements with industry leaders — commercial players, you know, those putting substantial investment into R&D and commercialization, such as Merck and Neurocrine — but also with academic centers, top-tier academic centers. As a general policy matter, and given confidentiality, we don't reveal specific deal structures, but in our corporate deck, we've laid out typical deal terms for every one of our deals, and those fall inside the boundaries we've disclosed previously. The deals contain multiple components. There are upfront payments, milestones, royalties, and an interplay among them; when it comes to platform access, there really aren't significant differences between deals signed with, say, a traditional commercial pharma and the academic centers; on the business side, it would clearly be quite unusual for an academic center to commercialize a drug by itself. Clearly, these folks possess leading, leading-edge biology; they typically wish to translate that into therapeutics that subsequently get spun out into companies. The sole distinction is that we'll include special provisions that specifically address how those economics will function when the academic institution decides to out-license the program or build a company around it. Fundamentally, they're quite similar. Certain clauses simply fit an academic environment better.
Robyn Karnauskas
analystThat's genuinely useful, and I suppose my next question is that a billion dollars is a huge amount. Given that you've been collaborating with these businesses, have you managed to secure a bit more transparency regarding the criteria you require before those milestones get paid out? One more thing from me, and apologies for piling on so many, you rarely mention OmniDeep, and I realize you hold the view that immune responses rooted in nature work best, but I'm curious whether you'd be open to using OmniDeep platforms for AI and ML-driven in silico antibody design. Everyone's talking about it lately, so I figured it was worth asking. Thanks.
Matt Foehr
executiveYeah, sure.
Kurt Gustafson
executiveRegarding the first part, financially speaking, the way these deals are set up is really the same as how our other deals are set up, correct? Usually there are clinical stage milestones as they move through the clinic, plus royalties. What differs is that the payment amounts are bigger, mostly as a result of the exclusivity under which we have written these deals. On the antibody side, everything people are pursuing involves non-exclusive targets, while for the ion channels, those targets are being licensed on an exclusive basis, and because of that, that is what drives the larger economics. But there is nothing necessarily unusual about the kinds of things involved. They fit within that same sort of deal structure of upfront payment and milestones and royalties.
Matt Foehr
executiveSure, Robyn — glad to address the AI topic. Of course, when it comes to tech, or sectors that get a lot of public attention, or are hyped up in the public eye, this is a question that comes up often. OmniDeep is what we call our in silico suite, built for therapeutic antibody discovery and optimization, and it's genuinely integrated across our many technologies and capabilities. Structural modeling is part of it, along with large — extremely large — multi-species antibody databases, plus AI and machine learning sequence models, among other things. It genuinely enables better identification and optimization of candidates emerging from our technology. Now, at the heart of what you're asking — sure, there's plenty of conversation about AI and how it's used, like purely AI-driven methods. What I think may be less widely grasped is that there are genuinely some significant caveats and constraints there, which is exactly why we see such strength in combining the biological intelligence of our animals with our AI capabilities. We've actually relied on in silico and AI tools in our downstream efforts for quite some time — particularly in screening, and some of our ion channel and transporter work. Our organization holds deep expertise in this area, which we introduced under the OmniDeep concept in Q2, though these approaches have been embedded across our company and technology, driven by a commitment to cutting-edge, solid science, for a very long while. In fact, over 2 years back, we struck a deal with Landing AI covering the vision aspect of AI, which we folded into our exploration platform effectively — and that's turned into a real standout success in terms of how we use screening. On the technical side, I'd note that purely AI-based methods carry plenty of constraints, so OmniDeep's real strength lies in pairing it with what I'd describe as the biological intelligence of our transgenic animals. That's because a well-engineered transgenic animal system essentially contains, as built-in natural checkpoints, many of the assays required to pick a winning antibody. So instead of only running things in a model, you can effectively screen and evaluate millions of distinct sequence possibilities, and naturally, the biological system filters them out. Beyond that, we apply AI in additional downstream ways using vast datasets, and that, I believe, is the source of much of that strength. I realize that got somewhat technical, but I hope it's clear.
Robyn Karnauskas
analystExcellent. Many thanks.
Stephen Willey
analystHello there, good afternoon, and thanks for fielding the questions. I appreciated hearing some of the macro observations you shared. I'm aware that a number of your peers have been discussing that topic recently. So, on the discovery program side, have you observed any meaningful rise in attrition? Given the reprioritization of R&D spending and the broader pipeline streamlining efforts emerging across the sector, would you view that as a more reliable proxy for some of these macro pressures?
Matt Foehr
executiveYes. That's a really excellent question, Steve. I would say there's genuinely nothing particular to report regarding attrition. As we mentioned, and I'll state this right at the start, attrition is simply a normal component of the pharmaceutical business, which we all understand. A great many things don't succeed, and so the presence of attrition is clearly to be expected; during the most recent quarter, the only attrition we observed was within the discovery phase, and solely among discovery stage assets. If you look back a bit further, in Q4 of last year, we experienced our first program attrition at the clinical stage. Two partners had withdrawn from certain therapeutic areas or specific therapeutic areas. Those assets themselves might hold promise in other hands, yet they are no longer counted within our program total. I mention that by way of illustration. It's tough to determine. Is this a macro phenomenon? Or is it simply larger partners concentrating on those particular instances? That's very hard to determine. I think giving you a precise answer to your question is difficult, but these are all metrics we track constantly, and we clearly continue having in-depth conversations with our partners. I hope that provides a bit more clarity.
Stephen Willey
analystAll right. Regarding the ongoing work in the ion channel area, I realize these are, once more, essentially licensed on a target-exclusive basis. For those targets already claimed by GSK or Roche — and I gather every one of them is tough to drug — how would you describe the targets they've picked when ranked among the hardest things to accomplish inside the ion channel field? Within the target universe, how much additional green space do you figure you have across roughly the coming 1, 3, and 5 years? Thank you.
Matt Foehr
executiveYes, terrific question, Steve. As you know, on the description side, there are, clearly, a considerable number of confidentiality matters and other considerations involving partners that we always honor, naturally. The GSK partnership concerns particular targets for neurological disorders; it sits at the discovery stage, and the deal was initially signed a couple of years back, so it has advanced nicely. Naturally, we reported the milestone during this quarter. I'll simply note that when people go after ion channels and transporters, those are typically viewed as high-value targets, correct? Speaking broadly, I believe GSK possesses a genuinely ambitious innovation agenda here. They have said publicly that their aim is to improve the health of 2.5 billion people positively by the close of 2030. That goal is truly aggressive and ambitious, and we're delighted to work alongside them. In my view, these are programs where we hold unique capabilities along with cell lines, reagents, and other assets, plus high-throughput screening, you know, and the capacity to draw on multiple modalities — which I believe are the sort of things capable of bringing in additional partnerships of this kind down the road.
Stephen Willey
analystGreat. Thanks for taking the questions.
Analyst
analystHi, this is Jack on from Matt. Thanks for taking our questions. obviously, you recently just launched OmniDeep, and I was just kind of curious what the initial reception has been from your customers. Thanks.
Matt Foehr
executiveYeah. Thanks, Jack. I'd describe it as highly favorable. The launch happened at the PEGS conference in Boston in May. The response in that room was substantial — a major session, with strong attendance — and reactions from partners present came virtually right away. It remains something we're concentrating on, both regarding fresh programs and possibly adopting alternative strategies to boost the odds of success for certain current programs alongside partners. Clearly, our research and innovation group, along with our BD group, keeps working together on this as we discuss it with partners. The response has been extremely encouraging.
Analyst
analystI appreciate you answering my question.
Chad Wiatrowski
analystHello, Matt. Hello, Kurt. This is Chad, filling in for Steven Mah.
Matt Foehr
executiveHi there, Chad.
Chad Wiatrowski
analystYeah, congratulations on that GSK milestone. Could you go into a bit more depth on what sets your tech stack apart from competitors who likewise say these traditionally tough targets, like ion channels, represent an opportunity they're going after too?
Matt Foehr
executiveYeah, yeah, absolutely. Glad to say more on that. I'd say a handful of factors set our technology apart, right? The multispecies approach we're able to present sits at the foundation. On top of that, you know, we touched a bit on how committed we are to steadily growing what we can do in the ion channel area. Ours is a lengthy track record stretching back decades when it comes to establishing high-throughput screening usable across a range of modalities. I'd argue that matters enormously here and particularly across the industry as a whole, where the boundaries separating various approaches and modalities are getting deliberately and creatively crossed. I think we've reached a point where our ability to capitalize on that differs from what others can do. We've likewise assembled a broad collection of bespoke cell lines purpose-built to support discovery in these fields, in certain of these particular fields. That's a resource accumulated across a great many years, and pairing it with our remaining discovery, repertoire generation, and screening capabilities genuinely does, in my view, put us in a rather distinctive position. That, I believe, explains why companies such as GSK and Roche find us appealing for partnerships of this kind.
Chad Wiatrowski
analystThat's genuinely useful. I do see the better downstream economics on ion channels, and I appreciate it. Still, you have precedents where target exclusivity has produced fairly large upfront payments. Could there be a chance to capture some near-term upside here?
Kurt Gustafson
executiveWell, every deal turns into a negotiation, doesn't it? To the degree we demonstrate success, we're always attempting to use that as leverage for larger payments. And when we look back, much of the gap between this and the antibody business has really come down to exclusivity itself. Another point I'd raise about the ion channel area — and Matt touched on the expertise we bring. Usually, with these ion channel programs, a license exists for a target on an exclusive basis, yet we keep performing all of that work, so a substantial share of the service revenue we bring in originates on the ion channel side of the business. Often the partners prepay for it, and there was the example given today around the specific GSK program, where they put down $7 million upfront that got amortized across the research period; compared with the antibody side of that business, we can produce, say, outsized economics purely on a relative basis. Much of that, though, simply stems from the fact that it's structured on an exclusive basis.
Chad Wiatrowski
analystAppreciate you fellows letting me ask.
Kurt Gustafson
executiveSure thing. Appreciate it, Chad.
Brandon Carney
analystBrandon Carney here, filling in for Yuan. Appreciate you taking our question. You mentioned a bit about what you're observing at the discovery stage. Could you speak to the clinical stage when it comes to trial delays or cancellations? What have you noticed up to now with respect to the programs you're following in biologics development?
Matt Foehr
executiveYeah, Matt here. I'll take that, and Kurt might want to chime in as well. When we kicked off the year, we stated we anticipated 3 to 5 new clinical entrants for the year. By the close of Q2, we had actually reached 3 already. As of today, our focus is on a higher range of 4 to 5 for this year; we're witnessing solid clinical advancement, or graduation, into the clinical stage; we're happy this quarter to watch a few assets transition from discovery into preclinical, meaning they're getting ready to head into the clinic. The portfolio is progressing nicely. Kurt, is there anything you'd like to add?
Kurt Gustafson
executiveNo, I mean, yeah, honestly we haven't really witnessed much clinical attrition. When it comes to the clinical attrition that has occurred, it's resulted from partners pulling out of therapeutic areas rather than any kind of study failure or anything along those lines. You know, like Matt mentioned, attrition comes with this business, and it's going to happen. What we've experienced so far on the clinical side has really been, you know, quite impressive compared to, you know, what the industry typically sees.
Brandon Carney
analystAlright, thank you. That's useful. We have one final question. Has the Inflation Reduction Act caused any change in where interest lies regarding biologics development?
Kurt Gustafson
executiveSure, I'll offer a thought. Our operations are primarily focused on antibodies—that's where our business sits. Because of the advantages the Inflation Reduction Act has provided, it's likely a more appealing area for drug development. If we offered both small molecules and antibodies, would we observe more parties gravitating toward antibodies? That's hard to determine. We think our platform is excellent, and we keep drawing in new participants, which the four new deals signed during this quarter demonstrate. Matt, perhaps you have—
Matt Foehr
executiveYeah, I guess what I'd say is this — you know, antibody-based therapies tend to work out more often than small molecules do, scientifically and technically speaking. That difference in success rates has been pushing the industry to change over time. Obviously, that's a pattern we observe, hear about, and understand. Now, with the IRA, the law is going to let Medicare sit down with drugmakers and bargain over pricing for a chosen set of expensive medicines, beginning — I think — in 2026. There are carve-outs for the way those talks can take place, and so on. Biologic drugs get what I'd call a longer runway, and that could speed up industry interest and the move toward biologics that was already underway before the IRA came along. If anything, it might give that interest an extra push. The science itself, the odds of success, and the medical upside — given how precisely antibody-based medicines work and how predictable they are to develop — had already set that shift in motion. If anything, it could simply make it go faster.
Brandon Carney
analystAlright, I appreciate those remarks, and thank you for allowing us to ask.
Kurt Gustafson
executiveSure, thanks.
Matt Foehr
executiveThanks a lot, and I appreciate all of you joining us on this call today, along with the questions you've raised. We're eager to keep you posted about how things are going and to talk with you again next quarter, plus at a number of investment conferences we plan to attend over the next few weeks and into the fall; the Stifel Conference is one we'll be at soon. In addition, we'll be present at H.C. Wainwright, Cantor, and the Craig-Hallum Capital conferences, all taking place in New York during the fall. Until then, thank you for the interest you've shown in OmniAb, and thanks once more. Enjoy the rest of your day.
Operator
operatorThat wraps up today’s conference call, everyone. We appreciate your participation, and at this point you’re welcome to hang up. Thanks so much.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.